Affordable medicine is a grand challenge of our time.
OSP3 was a singular gathering of researchers, entrepreneurs, industry professionals, funders and NGOs and who want to achieve radical improvements in the way therapeutics are delivered to market in the 21st century.
Open source brings the promise of efficient, robust and inclusive routes to discovery. While great progress has been made in opening up the discovery and development of new medicines, there remain major barriers to open source medicines reaching patients. Our task in this meeting was to learn about and spark new initiatives, to understand the main challenges together and to propose new, realistic solutions for implementation.
This meeting followed the 1st OSP conference, which took place at the Bellagio Center, Lake Como, Italy in 2014, and the second, which took place at Castle Rauischholzhausen, Marburg, Germany in 2015. Partners and sponsors have included The Rockefeller Foundation, Open Society Foundations and Tata Trusts. The OSP3 meeting was sponsored by CRI Research, with support from DRUID - Giessen University.
Number of Attendees: small (~50) select group of the world's thought leaders, feeding significant “live” social media outreach
Partners and Sponsors: CRI-Paris, Cures Within Reach, DRUID, European & Developing Countries Clinical Trials Partnership, Harvard Global Health Institute, Mayo Clinic TB Center, Open Source Malaria, Open Source Pharma Foundation, Philipps-University Marburg, Sage Bionetworks, Tata Trusts
Venue: The newly renovated building of CRI, a global leader in open science and quantitative approaches to biology, situated in the heart of Paris.
Wengsi Chiu (Open Source Pharma,
Victoria Diez (CRI, email@example.com)
Alina Grenier-Arellano (Open Source Pharma, firstname.lastname@example.org)
Peter Kolb (University of Marburg,
Ariel Lindner (CRI, email@example.com)
Jaykumar Menon (Harvard University,
Matthew Todd (University College London,